Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zura BioFRA:94E -1.29%25 Market Cap is €436.73 Mil as of Jul. 27, 2026. GuruFocus rates FRA:94E with a GF Score™ of 25/100. Among 1,422 Biotechnology companies, Zura Bio ranks better than 71.94% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Zura Bio's share price for the quarter that ended in Mar. 2026 was €4.96. Zura Bio's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 94.88 Mil. Therefore, Zura Bio's market cap for the quarter that ended in Mar. 2026 was €470.61 Mil.
Zura Bio's quarterly market cap
increased
from Sep. 2025 (€169.05 Mil) to Dec. 2025 (€334.51 Mil) and
increased
from Dec. 2025 (€334.51 Mil) to Mar. 2026 (€470.61 Mil).
Zura Bio's annual market cap
declined
from Dec. 2023 (€182.22 Mil) to Dec. 2024 (€154.10 Mil) but then
increased
from Dec. 2024 (€154.10 Mil) to Dec. 2025 (€334.51 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Zura Bio's Enterprise Value for Today is €238.43 Mil.
Zura Bio (FRA:94E) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Zura Bio Market Cap Related Terms
Zura Bio Market Cap Historical Data
* Premium members only.
The historical data trend for Zura Bio's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:94E vs ASMB, ARTV, EIKN: Market Cap Comparison
For the Biotechnology subindustry, Zura Bio's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zura Bio Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zura Bio's Market Cap distribution charts can be found below:
* The bar in red indicates where Zura Bio's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Zura Bio's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zura Bio (FRA:94E) has a Market Cap of €436.73 Mil as of Jul. 27, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Zura Bio and its competitors. According to the industry distribution chart, Zura Bio ranks #399 out of 1422 companies in the Biotechnology industry, placing it in the top 28.1%.
Is Zura Bio's Market Cap too high?
Zura Bio's current Market Cap is €436.73 Mil. Based on the distribution chart, Zura Bio ranks #399 out of 1422 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Zura Bio has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Zura Bio's Market Cap compare to ASMB and ARTV?
According to the Biotechnology industry distribution chart, Zura Bio ranks #399 out of 1422 companies for Market Cap. This puts Zura Bio in the upper half of its industry. The industry median Market Cap is 110.94. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 110.94, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Zura Bio and its competitors. For the Biotechnology industry, the median Market Cap is 110.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zura Bio's current Market Cap is €436.73 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zura Bio stock overvalued right now?
Zura Bio (FRA:94E) has a current Market Cap of €436.73 Mil. The current Market Cap is €436.73 Mil. Zura Bio's overall GF Score™ is 25/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Zura Bio (FRA:94E), the current Market Cap is €436.73 Mil as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
25GF Score
Get the complete analysis for FRA:94E
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:94E has been successfully added to your 
